Freedom of Information request on Yellow Card reports involving COVID-19 vaccines (FOI 21-510)
Published 13 August 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-7-june-2021/freedom-of-information-request-on-yellow-card-reports-involving-covid-19-vaccines-foi-21-510
7th June 2021 FOI 21/510
Dear
Thank you for your Freedom of Information (FOI) request dated 8th May 2021 where you requested the following:
how many yellow card reports have been made involving the covid vaccines. I’d like to know how many people have died so far and also how many people have had adverse reactions from the jabs
The MHRA is collecting data concerning any adverse reactions observed to vaccine treatment through our Yellow Card Scheme. We are regularly publishing Yellow Card data associated with COVID-19 vaccinations. Yellow Card data for drugs is routinely published on the Yellow Card website, with vaccine data available on request. However, for COVID-19 vaccinations we are proactively publishing details of adverse drug reactions received, including MHRA assessment of the data to provide context. Please note this data is updated weekly.
https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely,
FOI Team, Vigilance and Risk Management of Medicines Division